Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Still a Buy?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) gapped up prior to trading on Monday. The stock had previously closed at $14.95, but opened at $16.00. Ono Pharmaceutical shares last traded at $16.00, with a volume of 192 shares traded.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. One analyst has rated the stock with a Hold rating. According to MarketBeat.com, Ono Pharmaceutical has a consensus rating of “Hold”.

Ono Pharmaceutical Price Performance

The firm has a fifty day moving average price of $15.13 and a two-hundred day moving average price of $14.70. The company has a quick ratio of 2.86, a current ratio of 3.28 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $7.52 billion, a P/E ratio of 15.24 and a beta of 0.38.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.